ATE543789T1 - Herstellung von alkylsubstituierten 2-desoxy-2- fluor-d-ribofuranosylpyrimidinen und -purinen und derivaten davon - Google Patents

Herstellung von alkylsubstituierten 2-desoxy-2- fluor-d-ribofuranosylpyrimidinen und -purinen und derivaten davon

Info

Publication number
ATE543789T1
ATE543789T1 AT05775359T AT05775359T ATE543789T1 AT E543789 T1 ATE543789 T1 AT E543789T1 AT 05775359 T AT05775359 T AT 05775359T AT 05775359 T AT05775359 T AT 05775359T AT E543789 T1 ATE543789 T1 AT E543789T1
Authority
AT
Austria
Prior art keywords
ribofuranosylpyrimidines
fluorod
desoxy
purines
derivatives
Prior art date
Application number
AT05775359T
Other languages
English (en)
Inventor
Peiyuan Wang
Byoung-Kwon Chun
Junxing Shi
Jinfa Du
Wojciech Stec
Jeremy Clark
Original Assignee
Pharmasset Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasset Inc filed Critical Pharmasset Inc
Application granted granted Critical
Publication of ATE543789T1 publication Critical patent/ATE543789T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/173Purine radicals with 2-deoxyribosyl as the saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/073Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06Aminosugars
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT05775359T 2004-07-21 2005-07-21 Herstellung von alkylsubstituierten 2-desoxy-2- fluor-d-ribofuranosylpyrimidinen und -purinen und derivaten davon ATE543789T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58986604P 2004-07-21 2004-07-21
US60823004P 2004-09-09 2004-09-09
PCT/US2005/025916 WO2006012440A2 (en) 2004-07-21 2005-07-21 Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives

Publications (1)

Publication Number Publication Date
ATE543789T1 true ATE543789T1 (de) 2012-02-15

Family

ID=35786706

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05775359T ATE543789T1 (de) 2004-07-21 2005-07-21 Herstellung von alkylsubstituierten 2-desoxy-2- fluor-d-ribofuranosylpyrimidinen und -purinen und derivaten davon

Country Status (17)

Country Link
EP (2) EP2348029A1 (de)
JP (2) JP5078612B2 (de)
KR (2) KR101236669B1 (de)
CN (1) CN102199181B (de)
AT (1) ATE543789T1 (de)
AU (2) AU2005267051B2 (de)
CA (2) CA2735079C (de)
DK (1) DK1773856T3 (de)
ES (1) ES2386005T3 (de)
HK (1) HK1106249A1 (de)
IL (2) IL180832A (de)
MX (1) MX2007000803A (de)
NZ (1) NZ552927A (de)
PL (1) PL1773856T3 (de)
PT (1) PT1773856E (de)
RU (1) RU2407747C2 (de)
WO (1) WO2006012440A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20030036189A (ko) 2000-05-26 2003-05-09 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
US7429572B2 (en) 2003-05-30 2008-09-30 Pharmasset, Inc. Modified fluorinated nucleoside analogues
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
WO2006031725A2 (en) 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
SI2084174T1 (sl) * 2006-10-10 2013-10-30 Gilead Pharmasset Llc Priprava nukleozidov ribofuranozil pririmidinov
ATE542810T1 (de) * 2006-12-18 2012-02-15 Hoffmann La Roche Verfahren zur herstellung von 3,5-di-omikron-acyl-2-fluor-2-c-methyl-d-ribono gamma-lacton
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
WO2008090046A1 (en) * 2007-01-23 2008-07-31 F. Hoffmann-La Roche Ag Alternate process for preparing 3,5-di-omicron-acyl-2-fluoro-2-c-methyl-d-ribono-gamma-lactone
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
EP2376088B1 (de) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituierte-2-Amino-Purin-Nukleosid-Phosphoramidate
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
JP5716500B2 (ja) 2010-06-03 2015-05-13 セントラル硝子株式会社 (2R)−2−フルオロ−2−C−メチル−D−リボノ−γ−ラクトン類前駆体の製造方法
AR084044A1 (es) 2010-11-30 2013-04-17 Pharmasset Inc Compuestos 2’-espiro-nucleosidos
JP2014514295A (ja) 2011-03-31 2014-06-19 アイディニックス ファーマシューティカルズ インコーポレイテッド ウイルス感染の治療のための化合物および薬学的組成物
WO2012142523A2 (en) 2011-04-13 2012-10-18 Gilead Sciences, Inc. 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
JP6073897B2 (ja) 2011-09-16 2017-02-01 ギリアド ファーマセット エルエルシー Hcvを処置するための方法
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
ES2771458T3 (es) 2013-01-31 2020-07-06 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales
JP6394588B2 (ja) * 2013-02-28 2018-09-26 セントラル硝子株式会社 (2R)−2−フルオロ−2−C−メチル−D−リボノ−γ−ラクトンの製造方法
JP6476591B2 (ja) * 2013-06-05 2019-03-06 セントラル硝子株式会社 (2R)−2−フルオロ−2−C−メチル−D−リボノ−γ−ラクトン類の製造方法
PL3650014T3 (pl) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Preparat złożony dwóch związków przeciwwirusowych
US10100075B2 (en) * 2013-12-23 2018-10-16 Mylan Laboratories Limited Process for the preparation of sofosbuvir
WO2016035006A1 (en) * 2014-09-01 2016-03-10 Dr. Reddy’S Laboratories Limited Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir
WO2016042576A1 (en) 2014-09-16 2016-03-24 Cadila Healthcare Limited Co-crystal of sofosbuvir and amino acid and process for preparation thereof
CN104327138B (zh) * 2014-10-21 2017-05-10 齐鲁制药有限公司 Psi‑7977中间体化合物的制备方法
USD791845S1 (en) 2015-09-22 2017-07-11 Samsung Electronics Co., Ltd. Door guard for refrigerator
USD791200S1 (en) 2015-09-24 2017-07-04 Samsung Electronics Co., Ltd. Door guard for refrigerator
US10239910B2 (en) 2016-07-20 2019-03-26 Optimus Drugs (P) Limited Process for the preparation of sofosbuvir
CN109422710B (zh) * 2017-08-28 2022-06-21 常州制药厂有限公司 一种索非布韦氟内酯中间体的制备方法
CN111362989B (zh) * 2020-03-19 2022-03-08 江苏工程职业技术学院 一种索非布韦关键中间体的制备方法
WO2021202669A2 (en) 2020-04-01 2021-10-07 Reyoung Corporation Nucleoside and nucleotide conjugate compounds and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US6462191B1 (en) * 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
CN1267446C (zh) * 2001-01-22 2006-08-02 默克公司 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物
US20060264389A1 (en) * 2002-07-16 2006-11-23 Balkrishen Bhat Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7429572B2 (en) * 2003-05-30 2008-09-30 Pharmasset, Inc. Modified fluorinated nucleoside analogues

Also Published As

Publication number Publication date
WO2006012440A3 (en) 2006-07-27
AU2011200941A1 (en) 2011-03-24
CN102199181B (zh) 2014-09-17
EP1773856A4 (de) 2010-10-13
CA2574651A1 (en) 2006-02-02
JP5351919B2 (ja) 2013-11-27
EP2348029A1 (de) 2011-07-27
EP1773856A2 (de) 2007-04-18
PT1773856E (pt) 2012-05-14
IL180832A0 (en) 2007-06-03
JP2008507547A (ja) 2008-03-13
RU2007106574A (ru) 2008-08-27
WO2006012440A2 (en) 2006-02-02
WO2006012440A8 (en) 2011-06-16
CA2735079C (en) 2013-11-05
JP2011148817A (ja) 2011-08-04
MX2007000803A (es) 2007-04-02
AU2005267051B2 (en) 2011-07-14
JP5078612B2 (ja) 2012-11-21
PL1773856T3 (pl) 2013-01-31
IL180832A (en) 2011-07-31
HK1106249A1 (en) 2008-03-07
CA2735079A1 (en) 2006-02-02
KR20070114344A (ko) 2007-12-03
NZ552927A (en) 2010-05-28
IL211606A0 (en) 2011-05-31
DK1773856T3 (da) 2012-05-21
KR101235548B1 (ko) 2013-02-21
CA2574651C (en) 2013-05-21
RU2407747C2 (ru) 2010-12-27
AU2005267051A1 (en) 2006-02-02
KR101236669B1 (ko) 2013-02-22
EP1773856B1 (de) 2012-02-01
ES2386005T3 (es) 2012-08-07
AU2011200941C1 (en) 2012-05-10
KR20110034699A (ko) 2011-04-05
CN102199181A (zh) 2011-09-28
AU2011200941B2 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
ATE543789T1 (de) Herstellung von alkylsubstituierten 2-desoxy-2- fluor-d-ribofuranosylpyrimidinen und -purinen und derivaten davon
NO20062062L (no) Procsesser for preparering av forskjellige former for (S)-(+)-clopidogrel bisulfat
EA200500920A1 (ru) Стабильный пенистый крем
ATE454938T1 (de) Düsen und komponenten davon sowie herstellungsverfahren dafür
DK1343782T3 (da) Pyrimidinaminer som angiogenesemodulatorer
UY27143A1 (es) Inhibidores de sulfonamida lactama de fxa y método
DK1633726T3 (da) Pyrimidinderivater, der er egnede til behandling af CRTH2-formidlede sygdomme
ATE500254T1 (de) Die replikation von hiv hemmende purinderivate
TR201908974T4 (tr) Kiral 8-(3-amino-piperidin-1-il)-ksantinlerin imalatı için yöntem.
ATE551345T1 (de) Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
MX2007003085A (es) Preparacion de 2'-fluoro-2'-alquilo sustituido u otras ribofuranosil pirimidinas y purinas opcionalmente sustituidas y sus derivados.
NO20052058D0 (no) Behandling av influensa.
NO20073055L (no) Forbindelser til behandling av tilstander i de ovre luftveier
CR7043A (es) Derivados de eteres utiles como ganetes inhibidores de las isozimas pde4
DK2204374T3 (da) Nucleosidphosphonater og analoge deraf til behandling af HPV-infektioner
ATE392197T1 (de) Medizinische vorrichtungen und herstellungsverfahren dafür
DE602004017931D1 (de) Grundierungszusammensetzung für dekorierte Formteile, Klarlackzusammensetzung für dekorierte Formteile und dekorierte Formteile
ATE551046T1 (de) Polymere duftkapseln und ihre herstellung
DK1879580T3 (da) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolinderivater som lægemidler til behandling af infertilitet
MA25927A1 (fr) Procedes de production de substitues sulfanomide imidacotriazinones
DK1879581T3 (da) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-derivater som lægemidler til behandling af infertilitet
IS8164A (is) Hringtengdar amínafleiður, aðferðir til að framleiða þær og lyfjablöndur sem innihalda þær
DK1843771T3 (da) Anvendelse af pyrimidylaminobenzamider til behandling af sygdomme, der responderer på modulation af Tie-2-kinase-aktiviteten
ATE433466T1 (de) Herstellung von homopolymeren, copolymeren und terpolymeren aus substituierten styrolen